Compare Moderna, Inc. (MRNA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs New York Times Co — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: Moderna, Inc. is far larger — about 7.3× New York Times Co's market cap, and New York Times Co pays a 1.38% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and New York Times Co for 81 Days on average.
| MRNA | NYT | |
|---|---|---|
Market Cap | $78.65B | $10.74B |
Volume | 37,373,437 | 2,096,352 |
Sector | Health | Media |
52-Week High | $225.00 | $85.86 |
52-Week Low | $22.36 | $54.66 |
Typical Hold Time | 59 Days | 81 Days |
Enterprise Value | $74.80B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
The New York Times Company (NYT) trades at $66.60, up 2.62% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. Technical indicators show a bullish overall signal despite mixed moving averages, with key resistance at $67-68. The company maintains robust profitability with 13.19% net income margin and recently declared a $0.23 quarterly dividend payable October 22, 2026.
NYT presents a favorable investment case with 35% analyst buy ratings and $84 consensus price target suggesting 26% upside potential. Key opportunities include sustained digital subscription growth and AI-related legal developments, while risks involve the ongoing shareholder lawsuit alleging reporting bias and competitive pressures in digital media. The stock's current valuation at 27.75 P/E appears justified by its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
